Do serum neural autoantibodies prove brain involvement or explain cognitive symptoms?

Neural autoantibody testing can be informative in cognitive syndromes, but a serum result must be interpreted as one part of a syndrome-level assessment rather than as proof of brain-directed disease.

What a serum result means

• A validated antigen-specific assay supports immunoglobulin recognition of its intended neural target. This inference is stronger when testing is antigen-appropriate: cell-based assays better preserve native conformation for neuronal-surface antigens, whereas immunoblots for intracellular antigens can produce nonspecific isolated reactivity.
• Serum-only positivity has limited disease-level predictive value. In a 2024 diagnostic study, probable or definite autoimmune encephalitis/paraneoplastic neurologic syndrome occurred in 31% of serum-only positive patients, versus 91% of CSF-only positive patients.

CNS involvement and mechanism

• Circulating antibody detection does not demonstrate blood–brain-barrier transit, antibody presence in CNS tissue, or intrathecal antibody production.
• Interpretation is antigen-specific: CSF is relatively more sensitive for NMDAR, KLHL11, and GFAP antibodies, while serum is more sensitive for LGI1 and CASPR2. Paired serum–CSF testing is therefore central to establishing compartment concordance.
• Where relevant, an antigen-specific antibody index can help distinguish local CNS production from passive transfer. In a small glycine-receptor paired-sample cohort, all six evaluable patients showed intrathecal synthesis despite generally normal albumin quotients.

Cognitive symptoms and clinical implications

• Serum positivity alone does not establish that autoimmunity is causing cognitive symptoms. Attribution requires concordance among antibody type and assay, subacute or fluctuating clinical phenotype, CSF inflammation or intrathecal antibodies, MRI/EEG findings, seizures or focal deficits, and consideration of alternative causes.
• Immunotherapy response is also not diagnostic by itself; in autoimmune-dementia cohorts, improvement tracked more closely with inflammatory CSF and subacute/fluctuating presentation than antibody positivity alone.

Bottom line

• Serum neural autoantibodies may indicate analytic immune recognition, but they do not by themselves prove brain entry or explain this 74-year-old patient’s cognitive symptoms; paired CSF evaluation and phenotype-specific corroboration are needed.